Trial · NCT03138421
Central Pain Study for ABX-1431
NCT03138421, Phase 1, Completed, Abide Therapeutics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Central Pain Study for ABX-1431. Trials, record NCT03138421. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03138421
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Central Pain Study for ABX-1431
- NCT number
- NCT03138421
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 9 participants, actual
- Lead sponsor
- Abide Therapeutics
- Conditions
- Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Multiple Sclerosis, Longitudinally Extensive Transverse Myelitis
- Interventions
- ABX-1431 HCl, Placebo
- First posted
- 2017-05-03
- Last updated
- 2019-01-25
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in mean pain score between ABX-1431 HCl and placebo based on the Pain NRS-11 ordinal numeric rating scale | placebo, treatment (14 days) | The treatment difference of ABX-1431 HCl versus placebo is estimated from the change from baseline in daily NRS-11 Pain to the final 7 days of treatment in each two-week treatment period. Baseline levels of pain or taken from the final 7 days of treatment in the period preceding each double-blind treatment period. |
| Secondary | Short Form Brief Pain Inventory (SF-BPI) Scores | placebo, treatment (14 days) | Difference in the change from baseline between ABX-1431 HCl and placebo |
| Secondary | Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) | placebo, treatment (14 days) | Difference in the change from baseline between ABX-1431 HCl and placebo |
| Secondary | Patient Global Impression of Change (PGIC) score | placebo, treatment (14 days) | Difference in the change from baseline between ABX-1431 HCl and placebo |
| Secondary | Proportion of patients achieving and maintaining >30%, >50%, reduction in mean pain intensity score compared to baseline and cumulative proportion of responders' analysis | placebo, treatment (14 days) | Difference in the change from baseline between ABX-1431 HCl and placebo |
| Secondary | Actigraphically estimated parameters of sleep (WASO, TST, sleep efficiency, average overnight activity counts) and general activity measured by percentage of sedentary time, and moderate to high intensity activity | placebo, treatment (14 days) | Difference in the change from baseline between ABX-1431 HCl and placebo |
| Secondary | Sleep interference (NRS-11) A NRS-11 scale recording sleep interference due to transverse myelitis pain / central pain in the previous week (in which 0 = no interference and 10 = greatest possible interference) | placebo, treatment (14 days) | Difference in the change from baseline between ABX-1431 HCl and placebo |
| Secondary | ABX-11431 and metabolite M55 plasma PK | placebo, treatment (14 days) | Difference in the change from baseline between ABX-1431 HCl and placebo |
| Secondary | 2-AG hydrolysis in PBMC | placebo, treatment (14 days) | Difference in the change from baseline between ABX-1431 HCl and placebo |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03138421
GET https://conductscience.org/api/trials/v1/NCT03138421/registered